How to use Technologies offered

A search for a cancer, preclinical stage, synthetic opportunity would use the selection "Therapeutics, Diagnostics" in 'Sector', 'Cancerous, neoplasmatic' in 'Disease Category', 'Drugs, Small Molecule' in 'Technology' and 'Preclinical' in 'Development Stage'.

Selection of 'Enabling Technology, Platform Technology' in 'Sector' will identify all kinds of research technologies that can be used in more areas of life sciences than pharmaceuticals only.

Each technology profile gives the name of a company or academic institute as source of the offer, and a link allowing to contact the potential licensor. In most cases a profile includes a pdf covering the available non-confidential information as well as detailed contact data.

Registered users can create non-public notifications profiles which will inform them about new 'Technologies Offered' entries fitting their needs as specified. In addition these profiles allow them to filter the available information more comfortably.

Name

tripeptide for treatment of diseases linked to increased apoptotic rates

Organization name

Clinic Invent

Profile

Introduction

In multicellular organisms, homeostasis is maintained through a balance between cell proliferation and cell death. Physiologic cell death occurs primarily through an evolutionarily conserved form of cell suicide termed apoptosis. It is well known that several diseases are linked to increased apoptotic rates such as, autoimmune diseases, neurodegenerative disorders, myocardial infarction, stroke or inflammatory diseases such as Crohn’s disease.

Invention

The present invention is related to the tripeptide (l)Lys-(d)Pro-(l)Thr (KdPT) or pharmaceutically acceptable salts thereof for therapeutic, prophylactic therapeutic or cosmetic treatment of a disease with increased apoptosis, wherein the treatment has an antiapoptotic effect. Results of numerous experiments (e.g. expression of cytokeratin-18 in intestinal epithelial cells in vitro) indicate that administration of KdPT leads to significantly reduced apoptotic rates.

Patent situation

A European patent application has been filed.

Commercial use and advantages of the invention

Potential applications:

Use of KdPT as a new antiapoptotic agent may be indicated in treating ischemic disorders including after organ transplantation as well as cerebrovascular accidents such as ischemic stroke.

Advantages of the invention:

Though several diseases are linked to increased apoptotic rates, treatment regimes mostly are not targeting at antiapoptotic effects. Therefore, the use of KdPT as an antiapoptotic agent may exert synergistic effects in combination therapy with standard therapy.

Since KdPT is a structural related to the human a-melanocyte stimulating hormone, only few side-effects are expected.

To view the contact information, attachments and url of this profile you have to login into your account or register a new account: Login Register

Your feedback

Please click here to log in to view the complete profile.

 
 

latest entries